PHARMACEUTICAL IP

  • Offering
    • Evolve AI
      • Albert (Validity)
        • Validity analysis
        • Albert Construe (Claim construction)
      • Popper (Prosecution)
      • Franklin (Publication review)
      • AI for Sequences
    • Fractional IP counsel
    • Services
      • AI guidance
      • Competitive intelligence
      • Deals
      • Due diligence
      • Freedom to operate
      • IP strategy and communication
      • Oppositions and appeals
      • Patent drafting
      • Patent prosecution
      • Trade secrets
    • Technologies
      • Pharmaceuticals
      • Biologics
      • Cell & gene therapy
      • AI drug discovery
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Fractional IP counsel
    • Fractional IP counsel
    • What is fractional IP counsel?
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Evolve AI
    • Albert (Validity)
      • Validity analysis
      • Albert Construe (Claim construction)
    • Popper (Prosecution)
    • Franklin (Publication review)
    • AI for Sequences
  • Technologies
    • Pharmaceuticals
      • Dosing regimens
      • Formulations
      • Life cycle management
      • New indications
      • Platform technologies
    • Biologics
      • Antibodies
      • Antibody-drug conjugates (ADCs)
      • T cell engagers (TCEs)
    • Cell & gene therapy
      • CAR-T cell therapies
      • Gene therapies
      • In vivo CAR-T
      • Lipid nanoparticles (LNPs)
      • Macrophages (CAR-M)
      • mRNA therapeutics
      • Regenerative cell therapies
    • AI drug discovery
  • Insights
    • Articles
    • Pharma IP Toolkit
    • Evolve Guides
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Recognition
    • Join us
    • Contact us
  • Offering
    • Evolve AI
      • Albert (Validity)
        • Validity analysis
        • Albert Construe (Claim construction)
      • Popper (Prosecution)
      • Franklin (Publication review)
      • AI for Sequences
    • Fractional IP counsel
    • Services
      • AI guidance
      • Competitive intelligence
      • Deals
      • Due diligence
      • Freedom to operate
      • IP strategy and communication
      • Oppositions and appeals
      • Patent drafting
      • Patent prosecution
      • Trade secrets
    • Technologies
      • Pharmaceuticals
      • Biologics
      • Cell & gene therapy
      • AI drug discovery
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Fractional IP counsel
    • Fractional IP counsel
    • What is fractional IP counsel?
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Evolve AI
    • Albert (Validity)
      • Validity analysis
      • Albert Construe (Claim construction)
    • Popper (Prosecution)
    • Franklin (Publication review)
    • AI for Sequences
  • Technologies
    • Pharmaceuticals
      • Dosing regimens
      • Formulations
      • Life cycle management
      • New indications
      • Platform technologies
    • Biologics
      • Antibodies
      • Antibody-drug conjugates (ADCs)
      • T cell engagers (TCEs)
    • Cell & gene therapy
      • CAR-T cell therapies
      • Gene therapies
      • In vivo CAR-T
      • Lipid nanoparticles (LNPs)
      • Macrophages (CAR-M)
      • mRNA therapeutics
      • Regenerative cell therapies
    • AI drug discovery
  • Insights
    • Articles
    • Pharma IP Toolkit
    • Evolve Guides
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Recognition
    • Join us
    • Contact us
  • Offering
  • What is fractional IP counsel?
  • Evolve AI
  • Technologies
  • Insights
  • Our team
  • Offering
  • What is fractional IP counsel?
  • Evolve AI
  • Technologies
  • Insights
  • Our team

A more nuanced approach to the evidence standard for prior use (T 1311/21)

  • Technology: Chemistry
  • 7th February 2025
The EPO provides crucial guidance on the standard of proof in alleged prior use cases, advocating for a nuanced approach.
Gold bar dissolving into turquoise fragments at its centre on dark blue, Evolve abstract article image

This post is based on a previous article on IPKat.

The decision of the EPO Board of Appeal in T 1311/21 provides important guidance on evaluating standards of proof in cases of alleged prior use. The Board of Appeal suggests that there should be a nuanced approach to assessing this evidence, that moves beyond the traditional binary choice between the “balance of probabilities” and “beyond reasonable doubt”. 

Background: Evidence standard for prior use

Traditionally, EPO Boards of Appeal have applied different standards of proof depending on whether evidence of alleged prior use was within the power of one party or equally available to both parties. The case at issue concerned European patent EP2950075, owned by Horiba Ltd, relating to an on-road running exhaust gas test apparatus. The patent claimed an apparatus for vehicle exhaust gas testing comprising an information processing unit connected to a display that could acquire and process running data during road tests. The Opponent, AVL List GmbH, challenged the patent’s validity based on several grounds, including prior public use as evidenced by a user manual describing the invention. 

At Opposition, the patent was maintained in amended form, with the Opposition Division (OD) finding that disclosure of the invention prior to the priority date had not been proven. Both parties appealed the OD decision. The question for the Board of Appeal was whether the user manual had been made available to the public before the priority date without an obligation of confidentiality, and how to assess the standard of proof required given that the evidence was neither fully within the opponent’s control nor equally accessible to both parties.

A more nuanced standard to the assessment of evidence for prior use? 

In T 1311/21, the Board of Appeal addressed the longstanding dichotomy between “balance of probabilities” and “beyond reasonable doubt” standards, and questioned whether such a dichotomy in fact made sense. The Board of Appeal noted that EPO case law has applied different standards depending on whether evidence lies within the power of one party (requiring proof “beyond reasonable doubt”) or is equally available to both parties (where “balance of probabilities” suffices). However, in this case, the evidence of prior use fell into neither category cleanly. Whilst the manual originated from the Opponent, it had been delivered to a third party (Daimler AG) and the circumstances of its use were not exclusively within either party’s knowledge.

The Board of Appeal observed that a “binary approach to proof standards can turn out to be overly formalistic and simplistic” (headnote 2). Instead, the Board of Appeal emphasised that “what matters is the deciding body’s conviction on the occurrence of an alleged fact, taking into account the particular circumstances of the case and the relevant evidence before it.” (headnote 2, and r. 3.2.1). In support of moving away from an approach based on a rigid dichotomy, the Board of Appeal cited previous decisions T 1138/20 and T 1634/17. T 1138/20, for example, found that making a distinction between the above-mentioned standards is neither necessary nor mandated by case law. Similarly, in T 1634/17, it was found that there was no need to take a stand on the question which standard of proof to apply.

In the present case, the Board of Appeal was of the view that applying a more flexible approach to the assessment of evidence would align with the complex reality of many prior use cases, where evidence may be partially available to both parties, or may lie primarily with third parties. Rather than trying to force such situations into one of two categories, the Board of Appeal advocated for a holistic assessment of the evidence in its context. 

Importantly, however, the Board of Appeal also emphasised that the more flexible approach to assessing the evidence for prior use it proposed would not mean a lowering of the bar for proving prior use. On the contrary, the Board of Appeal argued, it would mean a greater focus on whether the totality of evidence, considered in its proper context, was convincing of an alleged prior use. Such an approach might include consideration of factors such as the nature of the alleged use, the commercial context, the reliability of the evidence, and any circumstances that might affect its availability to the parties.

Reliance on general terms of confidentiality 

Having decided on what approach it should take, the Board of Appeal reviewed the chain of evidence regarding the public availability of the user manual for the AVL MOVE System Control software. The OD had found the user manual not to be prior art, and so had not fully considered the novelty and inventive step of the claimed invention in view of the manual. Key evidence cited by the Opponent that the manual should be considered prior art included delivery notes showing the shipment of the user manual to another company, Daimler AG. The Board of Appeal was convinced by this evidence that the relevant version of the manual was delivered to Daimler AG before the patent’s priority date. 

The question then became whether conditions of confidentiality could be said to have applied to the manual. The Board rejected arguments from the patentee that the confidentiality of the manual was implied. Particularly, the Board of Appeal noted that user manuals for commercially available products are typically not subject to confidentiality obligations. 

The patentee also referenced the mention of AVL’s General Terms and Conditions in the delivery note and also noted standard industry practice. However, the Board of Appeal was not convinced by these arguments. First, the Board emphasised the commercial reality that the AVL MOVE system described in the user manual was not a product produced for a single customer, but for many, with the manual intended for delivery to all purchasers. The Board noted that imposing confidentiality obligations on such widely distributed user manuals would be impractical and nearly impossible to enforce. The Board emphasised that user manuals, by their nature, merely describe how to use an already purchased product and thus wouldn’t typically be subject to confidentiality restrictions. Additionally, the cited purchase documentation revealed that Daimler AG’s own purchasing conditions were applicable to the case, potentially neutralising any effect of AVL’s standard terms. 

The Board of Appeal concluded that the user manual was prior art and remitted the case back to the Opposition Division for an assessment of novelty and inventive step.

Final Thoughts

The issue of prior use is, of course, a hot topic at the moment as we await the outcome of the referral to the EBA in G1/23. The issue also came up in the recent decision concerning the morality of inventions derived from indigenous people by immoral means. As the Board of Appeal notes in the present case, both demonstrating and defending against an allegation of prior use can be challenging, as the form of evidence is often less than perfect. 

The Board of Appeal’s approach in this case suggests that future cases involving prior use should focus less on arguing about which standard of proof applies, and more on presenting comprehensive evidence that allows the deciding body to form a clear conviction about what occurred.

Further Reading

  • New EBA referral: When is prior use of a product excluded from the prior art for lack of enablement? 
  • The morality (and patentability) of inventions derived by immoral means (T 2510/18)

Related insights...

Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image

Post-published clinical data does not always save you (T 0251/25, Empagliflozin)

  • 3rd November 2026
Empagliflozin (Jardiance) is approved in the US for reducing the risk of cardiovascular death in adults with type 2 diabetes (T2D) and established cardiovascular disease, and in Europe for reducing the risk of cardiovascular death and hospitalisation for heart failure in adults with heart failure. The recent decision in T 0251/25 nonetheless found Boehringer Ingelheim’s…
Flight of gold steps with one turquoise glowing step on dark blue, Evolve abstract article image
Flight of gold steps with one turquoise glowing step on dark blue, Evolve abstract article image

Reformatio in peius survives a procedural violation (T 1168/24)

  • 2nd November 2026
Sometimes patent law is about procedures and not inventions. The appeal in T 1168/24 related to the lipid nanoparticle (LNP) technology behind the COVID-19 vaccines, opposed by Merck and Moderna. After two rounds of opposition and two appeals, the patent was revoked for added matter. Whilst the global litigation surrounding LNPs is interesting in its…
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image

The enablement paradox and the danger of definitions (Wyeth v AstraZeneca)

  • 6th October 2026
The Federal Circuit’s decision in Wyeth v AstraZeneca (No. 2024-2325) applied the enablement test to a dose invention. The case is an interesting contrast to the other recent case to apply enablement to a method of treatment claim, Teva v Eli Lilly.
Nested gold frames with a glowing turquoise centre on dark blue, Evolve abstract article image
Nested gold frames with a glowing turquoise centre on dark blue, Evolve abstract article image

Lack of clarity by the backdoor: An ambiguity “may simply result in a broader interpretation” (T 0977/25)

  • 4th October 2026
In T 0977/25, a Board of Appeal found that the word “it” in an amended method claim for an e-cigarette cartridge was ambiguous.
Gold bar dissolving into turquoise fragments at its centre on dark blue, Evolve abstract article image
Gold bar dissolving into turquoise fragments at its centre on dark blue, Evolve abstract article image

G1/25: What are the consequences?

  • 12th September 2026
Following the release of G1/25, questions have been circling as to what the decision means for the pending referral in G 1/26 and what the consequences (good or bad) are for applicants and patentees.
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image

BREAKING: When real doubt hits – G1/25 changes the description adaptation requirement for the worse

  • 4th September 2026
G 1/25, issued today, holds that the description must be adapted only where an “inconsistency” between the claims and description causes non-compliance with another requirement of the EPC.
Gold ribbon twisting once to reveal a turquoise underside on dark blue, Evolve abstract article image
Gold ribbon twisting once to reveal a turquoise underside on dark blue, Evolve abstract article image

New referral on claim interpretation and relevance of G1/24 to added matter confirmed (G1/26)

  • 23rd July 2026
We now have confirmation of a new referral to the EBA on claim interpretation (G1/26). As previously hinted, the Board of Appeal in T 0873/24 has decided to refer questions on the application of G1/24 to the assessment of added matter.
Gold block of two interlocking pieces with a turquoise joint on dark blue, Evolve abstract article image.
Gold block of two interlocking pieces with a turquoise joint on dark blue, Evolve abstract article image.

When do you file for a drug combination invention? (T 592/24)

  • 16th July 2026
Drug combination inventions are increasingly difficult to protect. File too early for a drug-combination invention and the application may lack the data to support the non-obvious effect of the combination. Wait for the trial read-out, and a competitor, or your own published protocol, may have already placed the invention in the public domain. 
Stack of gold slabs with a glowing turquoise middle layer on dark blue, Evolve abstract article image.
Stack of gold slabs with a glowing turquoise middle layer on dark blue, Evolve abstract article image.

Patenting the use of medical devices (T 0941/24)

  • 26th June 2026
Patenting medical devices in Europe is challenging. First, there is the problem that medical use claims are not permitted for medical devices, whilst simultaneously methods of treatment or surgery using a device are excluded from patentability. 
Gold ribbon twisting once to reveal a turquoise underside on dark blue, Evolve abstract article image
Gold ribbon twisting once to reveal a turquoise underside on dark blue, Evolve abstract article image

BREAKING: Imminent new referral to the EBA on the relevance of G1/24 to added matter

  • 6th May 2026
The Board of Appeal in T 873/24 has decided to refer questions to the Enlarged Board of Appeal (EBA) on the application of G1/24 (claim interpretation) to the assessment of added matter.
All Insights

evolve® is a trading entity of Evolve Intellectual Property Limited. Evolve Intellectual Property Limited is regulated by the Intellectual Property Regulation Board (IPReg). Details of the UK professional rules can be found on the IPReg website

registered address: 49 Greek Street, London, England, W1D 4EG

website out of house

© 2026 All Rights Reserved

Keep in touch

  • Subscribe
  • Contact us
  • Cookie Notice
  • Complaints Procedure
  • Privacy notice
  • Subscribe
  • Contact us
  • Cookie Notice
  • Complaints Procedure
  • Privacy notice